Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.65 |
| ▸ | SNCA | P37840 | 1/20 | 0.62 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.56 |
| ▸ | CA12 | O43570 | 5/20 | 0.54 |
| ▸ | CA9 | Q16790 | 5/20 | 0.54 |
| ▸ | CA1 | P00915 | 4/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | TYR | P14679 | 1/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | MET | P08581 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15711524 | 1.00 | LDHA (0.65) | LDHASNCAEPHX2PTGS1CA12 | |
| SCHEMBL546910 | 1.00 | LDHA (0.65) | LDHASNCAEPHX2PTGS1CA12 | |
| SCHEMBL30192596 | 1.00 | LDHA (0.65) | LDHASNCAEPHX2PTGS1CA12 | |
| SCHEMBL9231443 | 0.95 | LDHA (0.60) | LDHASNCAEPHX2PTGS1CA12 | |
| SCHEMBL26485996 | 0.91 | LDHA (0.58) | LDHASNCAEPHX2PTGS1CA12 | |
| SCHEMBL30429113 | 0.91 | LDHA (0.58) | LDHASNCAEPHX2PTGS1CA12 | |
| SCHEMBL2928116 | 0.91 | LDHA (0.58) | LDHASNCAEPHX2PTGS1CA12 | |
| SCHEMBL15711514 | 0.89 | SNCA (0.66) | LDHASNCAEPHX2PTGS1CA12 | |
| SCHEMBL546975 | 0.89 | SNCA (0.66) | LDHASNCAEPHX2PTGS1CA12 | |
| SCHEMBL20944781 | 0.89 | SNCA (0.66) | LDHASNCAEPHX2PTGS1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 412 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108634-A1 | HIGH MOLECULAR WEIGHT MULTI-ARM POLYMERS AND MEDICAL HYDROGELS FORMED THEREFROM | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2026-04-23 | — | — | US | claimed |
| EP-4724117-A2 | METHOD OF TREATING AN ARTICULAR CONDITION OR A CONDITION OF A BONY CANAL | Ocular Therapeutix, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| US-12599624-B2 | Biodegradable lung sealants | ETHICON, INC. (US) | 2026-04-14 | — | — | US | claimed |
| EP-4580690-B1 | BIODEGRADABLE LUNG SEALANTS | ETHICON INC (US) | 2026-03-18 | — | — | EP | claimed |
| US-20260035435-A1 | APPROACHES FOR THE SELECTIVE DEPLETION OF PLA2R-SPECIFIC ANTIBODIES | Astero BioPharma LLC (US) | 2026-02-05 | — | — | US | claimed |
| EP-4683964-A2 | POLY(ETHYLENE GLYCOL) BASED DENDRIMER-LIKE HYPERBRANCHED MACROMOLECULES, METHODS OF PREPARATION AND USE THEREOF | Ocular Therapeutix, Inc. (US) | 2026-01-28 | — | — | EP | claimed |
| EP-4676553-A1 | MEDICAL SEALANTS | Ethicon, Inc. (US) | 2026-01-14 | — | — | EP | claimed |
| US-20250382348-A1 | APPROACHES FOR THE SELECTIVE DEPLETION OF PLA2R-SPECIFIC ANTIBODIES | Astero BioPharma LLC (US) | 2025-12-18 | — | — | US | claimed |
| EP-4630058-A2 | CHEMICAL TISSUE ABLATION WITH HYDROGEL MATRIX AND CORRESPONDING MEDICAL APPLICATIONS | Pramand LLC (US) | 2025-10-15 | — | — | EP | claimed |
| EP-4580694-A1 | SEALANTS FOR TISSUE CLOSURE | Ethicon, Inc. (US) | 2025-07-09 | — | — | EP | claimed |
| CN-115066232-A | Compositions and methods for treating ocular diseases | 视觉治疗股份有限公司 | 2022-09-16 | — | — | CN | claimed |
| US-20220218643-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES | BARINGS FINANCE LLC, AS AGENT | 2022-07-14 | — | — | US | claimed |
| US-20220175672-A1 | COMPOSITIONS AND METHODS FOR SUSTAINED DRUG RELEASE FROM AN INJECTABLE HYDROGEL | CONTRALINE INC (US) | 2022-06-09 | — | — | US | claimed |
| WO-2022103944-A1 | HYDROGELS FORMED IN SITU AND COMPOSITION DESIGN FOR INTRAUTERINE USE | Pramand LLC (US) | 2022-05-19 | — | — | WO | claimed |
| US-20220143276-A1 | HYDROGELS FORMED IN SITU AND COMPOSITION DESIGN FOR INTRAUTERINE USE | Pramand LLC | 2022-05-12 | — | — | US | claimed |
| WO-2022066891-A1 | SUSTAINED RELEASE BIODEGRADABLE INTRACANALICULAR INSERTS COMPRISING A HYDROGEL AND AN ACTIVE AGENT | OCULAR THERAPEUTIX, INC. (US) | 2022-03-31 | — | — | WO | claimed |
| WO-2022066884-A1 | SUSTAINED RELEASE BIODEGRADALBE INTRACANALICULAR INSERTS COMPRISING A HYDROGEL AND CYCLOSPORINE | OCULAR THERAPEUTIX, INC. (US) | 2022-03-31 | — | — | WO | claimed |
| EP-3973952-A1 | SUSTAINED RELEASE BIODEGRADABLE INTRACANALICULAR INSERTS COMPRISING A HYDROGEL AND CYCLOSPORINE | Ocular Therapeutix, Inc. (US) | 2022-03-30 | — | — | EP | claimed |
| WO-2022060904-A1 | COMPOSITIONS AND METHODS FOR EXPRESSION OF T-CELL RECEPTORS WITH SMALL MOLECULE-REGULATED CD40L IN T CELLS | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-03-24 | — | — | WO | claimed |
| CN-112941044-A | Novel gene for synergistically controlling plant yield and stress resistance traits and application thereof | 中国科学院分子植物科学卓越创新中心 | 2021-06-11 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12599624-B2 | Biodegradable lung sealants | CD44, TTPA, PLOD3 | LDHA 162/4885SNCA 4700/4885EPHX2 106/4885 |
| US-20220218643-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES | PDE6C, PDE6H, PDE6A | LDHA 2106/4885SNCA 3669/4885EPHX2 637/4885 |
| US-20260035435-A1 | APPROACHES FOR THE SELECTIVE DEPLETION OF PLA2R-SPECIFIC ANTIBODIES | PLA2G2D, FCGR2A, PLA2R1 | LDHA 3941/4885SNCA 4312/4885EPHX2 2618/4885 |
| US-20260108634-A1 | HIGH MOLECULAR WEIGHT MULTI-ARM POLYMERS AND MEDICAL HYDROGELS FORMED THEREFROM | KIT, KLK3, CD44 | LDHA 738/4885SNCA 4537/4885EPHX2 2066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.